In clinical trials, nausea (12-22%), diarrhea (12-16%), vomiting (5-9%), constipation (6-7%), abdominal pain (6-9%), and dyspepsia (7-10%) were frequently reported
Studies have shown that patients using GLP-1 receptor agonists, alongside lifestyle modifications, can achieve an average weight reduction of 1015% of their body weight over time with improvements in blood sugar control, blood pressure, and cholesterol levels
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has emerged as a treatment option for PCOS-related weight gain and insulin dysregulation
I walked 30 minutes most days and did light resistance training twice a week
Is it any good, or are you better off spending more for HGH
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA internal medicine vol